Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Colleen’s Dream Foundation Donates $10,000 to Johns Hopkins Medicine for Ovarian Cancer Research
  • USA - English


News provided by

Colleen's Dream Foundation

Jul 24, 2014, 03:00 ET

Share this article

Share toX

Share this article

Share toX

Colleen Drury - The Inspiration for Colleen's Dream Foundation
Colleen Drury - The Inspiration for Colleen's Dream Foundation

Phoenix, AZ (PRWEB) July 24, 2014 -- Colleen’s Dream Foundation, in partnership with Fidelity National Title Agency, has donated $10,000 to Johns Hopkins Medicine to fund ovarian cancer research, according to Colleen’s Dream Foundation President Billy Cundiff.

According to Cundiff, this is the second year in a row Colleen's Dream Foundation has supported ovarian cancer research at Johns Hopkins Medicine.

"Prevention is probably the most effective way of reducing morbidity and mortality from ovarian cancer." - Dr. Robert Kurman, Director of the Division of Gynecologic Pathology at Johns Hopkins Medicine

Post this

“One of the main goals of Colleen's Dream Foundation is to work with promising young investigators at some of the top research hospitals and universities that are researching ovarian cancer,” says Cundiff. "So it only makes sense that we are once again supporting ovarian cancer research being conducted at Johns Hopkins.”

Cundiff says this year's grant to Johns Hopkins will go to Dr. Hiroyasu Kashima.

According to Dr. Robert Kurman, Director of the Division of Gynecologic Pathology at Johns Hopkins Medicine, Dr. Kashima’s research currently focuses on the prevention of ovarian cancer.

“Prevention is probably the most effective way of reducing morbidity and mortality from ovarian cancer,” says Kurman. “Dr. Kashima’s research, which focuses on re-purposing a drug that has been used for many years for use in preventing ovarian cancer, would be an important breakthrough.”

Kurman adds the grant from Colleen’s Dream Foundation will both support Dr. Kashima’s research and help to launch him as an independent ovarian cancer investigator.

“In his future work, Dr. Kashima will study the molecular mechanisms underlying how statins prevent the development of ovarian cancer,” says Kurman. “These studies will provide the biological basis for the development of clinical trials to determine whether statins can indeed prevent ovarian cancer in high-risk women.”

Cundiff, who is the kicker for the Cleveland Browns, says the $10,000 grant supporting Dr. Kashima's ovarian cancer research is a direct result of the sponsorship and support provided by Dustin Gaskey and Fidelity National Title Insurance Company in Phoenix, Arizona.

"Dustin and his team at Fidelity National Title have been amazing. Their dedication to Colleen's Dream and our mission is remarkable,” says Cundiff. “We are honored that they have joined us in supporting the valuable ovarian cancer research that Dr. Kashima is performing at Johns Hopkins."

Gaskey says it was an easy decision to partner with Cundiff and Colleen’s Dream Foundation to help fight ovarian cancer.

"As a father, a husband, a brother, and a son…participating with Colleen's Dream Foundation to assist in the early detection of ovarian cancer is a no brainier for us,” says Gaskey. “We thank the entire team for the opportunity to be a member of the Colleen's Dream Family."

ABOUT OVARIAN CANCER:

Ovarian cancer is often referred to as “the silent killer” because many women do not discover their disease until it is in the late stages, which leads to many women succumbing to the disease within a short period of time. Unlike cervical or breast cancer, ovarian cancer does not have a standardized early detection procedure. When it comes to women’s health, ovarian cancer proves to be one of the deadliest diseases.

ABOUT COLLEEN’S DREAM FOUNDATION:

Colleen’s Dream Foundation started in 2012 and supports research for early detection and improved treatment for ovarian cancer. The story of Colleen’s Dream started in 2007 when Colleen Drury – Nicole Cundiff’s mother and Billy Cundiff’s mother-in-law – was diagnosed with late-stage ovarian cancer. The family became aware of a new world that was filled with invasive surgery, harsh chemotherapy, and lots of uncertainty, and realized they needed to help others who were dealing with ovarian cancer.

Colleen’s Dream Foundation believes it is important to raise money for research that will lead to reliable early detection testing and improved treatment for ovarian cancer. Because so little is known about ovarian cancer in proportion to other women’s health issues, there is an incredible opportunity for research and education.

Go here to find out more about Colleen’s Dream Foundation.

Colleen's Dream Foundation is a qualified 501 (c)(3) tax exempt non-profit organization based in Phoenix, Arizona.

Admin, Colleen's Dream Foundation, +1 (480) 269-2266, [email protected]

Modal title

Colleen's Dream Foundation President and Cleveland Brown's Kicker Billy Cundiff
Colleen's Dream Foundation President and Cleveland Brown's Kicker Billy Cundiff
Colleen's Dream Foundation President and Cleveland Brown's Kicker Billy Cundiff

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.